We found that VEGFR2 expression was higher in grade III and IV glioma patients than that in grade II patients, and that VEGFR2 blockade inhibits glioblastoma cell growth via AKT-PGC1α-TFAM-mitochondria biogenesis signaling cascade. This evidence concerns the gene KDR and glioblastoma.